Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Intersect ENT, Inc. (NASDAQ: XENT).

Full DD Report for XENT

You must become a subscriber to view this report.


Recent News from (NASDAQ: XENT)

Intersect ENT's (XENT) CEO Lisa Earnhardt on Q1 2018 Results - Earnings Call Transcript
Intersect ENT Inc. (XENT) Q1 2018 Earnings Conference Call May 01, 2018 04:30 PM ET Executives Jeri Hilleman - Chief Financial Officer Lisa Earnhardt - President and Chief Executive Officer Analysts Chris Pasquale - Guggenheim Kristen Stewart - Deutsche Bank Ravi Misra - ...
Source: SeekingAlpha
Date: May, 01 2018 20:39
Intersect ENT Reports First Quarter 2018 Results
Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2018. Recent Business Highlights In April 2018, the company announced U....
Source: Business Wire
Date: May, 01 2018 16:05
Investor Expectations to Drive Momentum within AMN Healthcare Services, Cass Information, William Lyon Homes, AMAG Pharmaceuticals, Intersect ENT, and First Financial - Discovering Underlying Factors of Influence
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AMN Healthcare Services Inc (NYSE:AMN), Cass Information Systems, Inc (N...
Source: GlobeNewswire
Date: April, 24 2018 03:53
Intersect ENT to Present at Deutsche Bank and Bank of America Merrill Lynch Conferences
Intersect ENT, Inc. (Nasdaq: XENT ) today announced that management will present at Deutsche Bank’s 43 rd Annual Health Care Conference and at Bank of America Merrill Lynch 2018 Healthcare Conference. The Deutsche Bank Conference presentation is scheduled for May 9, 2018 at 10:4...
Source: Business Wire
Date: April, 17 2018 16:05
Intersect ENT to Report First Quarter 2018 Financial Results
Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its first quarter on May 1, 2018. The company expects to issue the release at approximately 4:00 p...
Source: Business Wire
Date: April, 16 2018 16:19
Intersect ENT Announces Launch of SINUVA(TM) Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
New Treatment Is Clinically Proven to Reduce Polyps and Symptoms of Nasal Congestion Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced U.S. commercial availability of the SINUVA™ (mome...
Source: Business Wire
Date: April, 02 2018 08:00
Large Opportunities And High Expectations Battling It Out At Intersect ENT
The history of Intersect ENT ( XENT ) should look very familiar to long-term investors in the med-tech sector. This company came to the market all shiny and new in 2014 with an interesting, differentiated product for an underserved market (chronic sinusitis) that offered $1 billion-plus reve...
Source: SeekingAlpha
Date: March, 28 2018 15:24
Intersect ENT's (XENT) CEO Lisa Earnhardt on Q4 2017 Results - Earnings Call Transcript
Intersect ENT Inc. (XENT) Q4 2017 Results Conference Call February 27, 2018 04:30 PM ET Executives Jeri Hilleman - Chief Financial Officer Lisa Earnhardt - President and Chief Executive Officer Analysts Bob Hopkins - Bank of America Merrill Lynch Matthew O'Brien - Piper Jaf...
Source: SeekingAlpha
Date: February, 27 2018 23:05
Intersect ENT beats by $0.07, beats on revenue
Intersect ENT (NASDAQ: XENT ): Q4 EPS of -$0.11 beats by $0.07 . More news on: Intersect ENT, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: February, 27 2018 16:14
Intersect ENT Reports Fourth Quarter and Full Year 2017 Results
Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and year ended December 31, 2017. Recent Business Highlights In December 2017, the U....
Source: Business Wire
Date: February, 27 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1740.3039.2040.4039.00233,039
2017-03-1014.9514.9515.226614.850512,793
2017-03-0914.6514.8515.8514.55321,004
2017-03-0814.2014.6514.8514.10223,823
2017-03-0713.9514.1014.2013.80186,104

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1532,69869,41147.1078Short
2018-08-1431,62398,39632.1385Cover
2018-08-1353,380122,41743.6051Short
2018-08-1028,309110,53325.6114Cover
2018-08-0927,561140,64519.5961Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on XENT.


About Intersect ENT, Inc. (NASDAQ: XENT)

Logo for Intersect ENT, Inc. (NASDAQ: XENT)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: XENT)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 01 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 23 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 23 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 28 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: February, 28 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 27 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 08 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 05 2018

       

       


      Daily Technical Chart for (NASDAQ: XENT)

      Daily Technical Chart for (NASDAQ: XENT)


      Stay tuned for daily updates and more on (NASDAQ: XENT)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: XENT)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in XENT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of XENT and does not buy, sell, or trade any shares of XENT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/